How genetic testing will help personalize your medicine

How genetic testing will help personalize your medicine
How genetic testing will help personalize your medicine

For much of modern medical history, treatment has centered around the average patient. Discovering treatments which work for most people, most of the time has been a necessary starting point. However, treating every patient according to an average is rarely the most effective treatment method and can potentially even cause harm in some cases.

When the U.S air force first designed its planes, it based every measurement of the cockpit — from the shape of the seat, to the height of the windshield, to the distance between seat and pedals — according to the average of dimensions from hundreds of pilots. Nevertheless, unexplainable crashes kept occurring.

A young researcher tasked with studying the conundrum discovered the flaw: no individual is average. By replacing the average-sized designs with new versions that could be adjusted to the individual, the problem was solved. Now we are discovering that the flaw of averages — and the need for personalization — is equally important in medicine.

We now know that certain ethnic groups are more susceptible to genetic conditions and respond differently to treatment. Likewise, women can present with very different symptoms to men for the same disease. Genetic testing moves vastly beyond even these differences — opening up treatment possibilities tailored to each specific individual.

Safer prescription and administration of drugs

Individual genetic makeup can uncover the difference between an effective drug and a severe allergic reaction. The study of how genes affect drug response is known as pharmacogenomics.

Genetic differences can determine which drugs are selected for treatment. One drug, ivacaftor or Kalydeco, is used to treat cystic fibrosis — it’s a first-line treatment, but only for the 5% of CF sufferers who have a specific genetic mutation.

In other cases, genetic testing is used to determine safe dosage levels. Thiopurine drugs are used to treat leukemia but can cause dangerous levels of bone-marrow suppression. The dosage window between effective treatment and toxicity is small. Individuals with a certain TPMT gene mutation are ten times more sensitive and have a ten times smaller window — genetic testing can identify them and protect them from these toxic side-effects.

Advanced cancer treatments

There are over 100 types of cancer and over a third of people will be diagnosed with one of them at some point during their lifetime. As the second biggest killer after heart disease, few people escape its effects — either via themselves or by seeing their loved ones affected.

Cancer is caused by mutations within a cell’s DNA which cause it to grow abnormally and uncontrollably. Some of these genetic mutations are caused by exterior damage — sun and smoking, for example — while some are present at birth. Genetic testing of an individual can evaluate their risk of developing certain types of cancer, but tumours can also be genetically tested to determine their makeup.

One of the first examples of personalized medicine, dating back to the 60s, involves a breast cancer hormone therapy known as tamoxifen. It targets estrogen receptors present on the cancer cells. Some breast cancers do not exhibit these receptors — rendering tamoxifen useless in these cases.

Understanding not only the genetic makeup of the patient, but of the tumour itself, has led to new classifications of tumours and new treatment opportunities. Whereas historically cancers have primarily been classified by the point they originate from on the body — lung, breast, pancreas — classifying them according to certain genomic markers opens up new avenues for effective treatment.

Early risk detection and intervention

Almost all disorders — whether genetic or acquired — are most effectively treated with early intervention. Genetic testing can be performed in utero, at birth and later in life.

Some disorders are easier to test for — those directly caused by a single gene or small number of genes, such as cystic fibrosis, sickle cell anaemia and muscular dystrophy. Where available, early intervention can be started as soon as the diagnosis is made, reducing the severity of the symptoms and improving quality of life.

Other more complex diseases can have dozens of gene variants associated with increased risk — over 90 gene variants have been linked to an increased risk of breast cancer. Genetic testing cannot directly say whether or not an individual will be affected in their lifetime, but high risk individuals can be better informed and prepared.

As modern genomics continues to advance, the progression towards personalized medicine will only accelerate. The potential benefits in terms of treatment efficacy, risk assessment and harm reduction cannot be understated.

The accumulation of this level of personal medical data, however, comes with its own set of challenges. Private genetic information can have significant consequences in the wrong hands — for example, when it comes to health insurance coverage. Patient security from both a technological and legal standpoint needs to be a priority, and here novel technologies such as blockchain can play an important role and create unprecedented value for the precision medicine ecosystem.

Boilerplate:

Shivom combines blockchain, A.I., DNA sequencing & cryptography to enable secure and personalized medicine. The Shivom platform works on principles of collaboration & integrity, allowing people to own, manage and monetize their data. By creating a web-marketplace, a network of genomic counselors, and a not-for-profit drug research unit, Shivom will build a global healthcare ecosystem, reaching even low-income countries where such services have not been previously available.

Ten benefits of genetic testing

Ten benefits of genetic testing
Ten benefits of genetic testing

Advances in genetic analysis and the rise of direct-to-consumer DNA tests have changed the way we think about genetic testing. Now more than ever, patients and consumers can learn about their own genetic material. How can we — both as individuals and as larger communities — benefit from genetic testing?

1. Detect birth defects in utero

Every parent hopes to welcome a healthy child into the world. The nine month gestation period — albeit with ultrasounds and regular doctor checkups — is a nerve-wrecking time for parents to be.

Prenatal genetic testing can identify some genetic disorders in utero, and is recommended for parents carrying recessive genes for conditions and mothers at risk from chromosomal abnormalities. Early identification of genetic disorders allow parents to better prepare for a special needs child or choose to terminate the pregnancy.

2. Identify genetic conditions at birth

The unfortunate reality of many genetic conditions is that they can never be cured, only controlled. However, early intervention is key to improved health outcomes and reducing disorder severity. In the United States, over 95% of babies are tested for a whole range of genetic diseases — about 3000 (out of over 4 million) test positive and can begin early treatment.

3. Guide family planning decisions

Some of the deadliest genetic disorders — cystic fibrosis, Huntington’s disease and Tay-Sachs, among others — are caused by recessive genes. Healthy adults who have never experienced symptoms can nevertheless carry the gene without ever being aware.

When two carriers have a baby, the child has a 25% chance of developing the full disorder. This is a particular risk in insular communities who tend to intermarry — there are genetic testing programs directed towards Ashkenazi Jews and the Amish for this reason. With the results from these tests, carriers can make informed decisions about who to marry and who to have children with.

Source: Jewish Genetic Disease Consortium

4. Reveal risk from genetic factors

When genetic disorders are controlled by a single gene, identification of carriers and affected individuals is relatively simple to test for. Humanity’s deadliest killers — cancer, heart disease, diabetes — are made up of a constellation of risk factors that are still not fully understood.

Advances in genetic testing allow you to know if you are at a greater risk from these diseases later in life, and how severely you may be affected. Additionally, identifying a genetic risk factor in one member of a family can prompt close family members to undergo genetic analysis and evaluate their own levels of risk.

5. Understand family history

The primary purpose of genetic testing has, for years, been medical. Now, people are taking matters into their own hands. Direct-to-consumer ancestry testing has seen meteoric growth — more people analyzed their DNA with such a test in 2017 than in all previous years combined.

The ability to analyze and own your personal genetic data is evidently a tempting proposition. But as companies collect ever larger quantities of DNA, the question of who owns this data and what happens to it after testing is ever present. In June 2018, email addresses and password information associated with over 90 million users of genealogy website MyHeritage were exposed during a hacking incident. Luckily, MyHeritage store DNA data on a separate system protected by extra layers of security.

6. Reach historically underrepresented groups

Historically, medical research has focused on one subset of the population — white males. Non-white ethnicities and women have been underrepresented in initial research as well as pre-clinical and clinical trials. There are known differences between the sexes in symptoms, risk factors and outcomes for a whole host of diseases — cardiovascular disease, stroke and asthma, to name a few.

This narrow focus results in adverse treatment effects and population-specific genetic disorders being overlooked. The availability and reach of direct-to-consumer genetic testing means future medical research has the potential to be far more inclusive and precise.

7. Personalize medical treatment

If one size fits all doesn’t apply to clothes, how could it possibly apply to medicine? Our previous point highlighted how different population groups respond differently to treatment — genetic testing goes even further by personalizing treatment to specific individuals.

Genetic factors can significantly affect the body’s response to drugs — the study of this field is known as pharmacogenomics. For example, Abacavir is a highly effective treatment option for most HIV sufferers, however causes severe side effects for 5–12% of the patients. Patients with the HLA-B*5701 gene variant were found to be most likely to suffer these side effects. By screening for this gene variant, another treatment option could be offered to these patients.

This personalization could even reduce the need for one of the most gruelling treatments of all — chemotherapy. A major international study recently found that some women with early-stage breast cancer could skip chemotherapy altogether, as long as their tumor showed specific genetic markers. Breast cancer tumors with these genetic markers can be treated solely using estrogen blockers.

8. Contribute to drug and treatment research

Millions more people undergoing genetic testing mean a potentially enormous sample pool for genetic research. More data available offers opportunities to identify new genes, better understand genetic conditions and formulate new drugs and treatment options.

Medical genetic testing has strict conduct codes around sample acquisition and informed consent of its subjects. The largest direct-to-consumer genetic tests share sequence data with non-profits and research institutions and other, for-profit parties — the data is used to develop new treatments that can help millions (and make millions). However, the individuals who supply the data do not benefit from these profits and can’t know if their samples have been used.

9. Relief from uncertainty

Knowing that you or your children may be at risk from a genetic condition is a deeply stressful experience. Many people affected report the feeling of “waiting for the other shoe to drop”, especially for conditions where symptoms typically appear late in life.

Undergoing a genetic test and receiving clear information can give great relief from this uncertainty. A negative diagnosis rules out the disease completely, while positive diagnoses can be used to undergo checkups more frequently and take steps for early intervention.

10. Make informed decisions

Knowledge is power. Whether prenatal, in early childhood or as an adult, knowing the level of risk is key towards directing future decisions. A person who undergoes genetic testing and discovers a predisposition towards skin cancer can take greater care to stay out of the sun, while someone predisposed towards Type 2 diabetes can preemptively make healthier diet choices. People with a predisposition to Alzheimer’s disease can slow the onset of symptoms through diet and taking up certain hobbies. Clear information means factors under the patient’s control can be identified and improved.

In an ideal case scenario, genetic testing should take place in conjunction with genomic counseling. The potential psychological effects — feelings of dread or hopelessness — of a poor diagnosis — should not be discounted. For most patients, however, the benefits of early intervention, improved treatment outcomes and increased sense of control far outweigh the negatives.

While the benefits to individuals are mostly positive, the collection of large amounts of genetic data raises questions about privacy, data protection and potential genetic discrimination. Will regulations that protect the individual keep pace with this new technology? That remains to be seen.

Introducing the Winner for Shivom’s Community T-shirt Contest

Introducing the Winner for Shivom’s Community T-shirt Contest
Introducing the Winner for Shivom’s Community T-shirt Contest

We are thrilled to have received such creative t-shirt design ideas. After browsing through all the submissions, we have decided to award Senthil as the winner of last month’s community t-shirt contest. Besides complying to the specification given, his design was creative and tied into our core product offering.

As promised, Senthil will receive 5,000 OMIX tokens. Thanks to everyone who participated and made this contest a stupendous success.
Stay tuned to know more about our next contest.

September Sickle Cell Awareness Campaign — Plus more updates about our Diabetes work in India

September Sickle Cell Awareness Campaign India
September Sickle Cell Awareness Campaign India

Following the announcement of our partnership with eMQT, Shivom asks the community to take a moment to reflect on the devastating genetic disorder Sickle Cell Disease (SCD)

SCD is a blood disease and particularly common in people with an African or Caribbean family background. Patients with SCD produce irregular shaped red blood cells that can cause complications because they don’t live as long as healthy blood cells and can’t carry enough oxygen around the body. Due to their shape, these blood cells can get stuck inside smaller blood vessels. This keeps blood from flowing and can cause pain and severe damage to parts of the body, ultimately leading to a reduced life expectancy.

We are inviting patients, physicians, and researchers to share their experiences with SCD on our social media channels.

Follow us, tweet at us @ProjectShivom, and use the hashtag #SickleCellAwareness OR you can send us your story to info@shivom.io

Read more about our work with SCD and our partnership with eMQT here

Moving Forward with Diabetes Pilot in India

Moving Forward with Diabetes Pilot in India

Towards the end of September our CEO, Henry Ines, and our Co-Founder and CSO, Dr. Axel Schumacher will again head to India to begin our Type II diabetes (T2D) pilot study in the state of Andhra Pradesh, located in the south-eastern part of the subcontinent. Together with our Indian partners, including a diagnostics clinic and local doctors, we will initiate the collection of DNA samples from diabetes patients and matched control subjects. Among others, the work will also involve setting up recruitment, sample logistics, educational programs, and standard operating procedures for the pilot and further projects. identification of biomarkers for accurate classification of patient subgroupsOur pilot program serves to bring precision medicine studies to the next era. The study will not only aim at finding genotypes that are specific to Indian sub populations but help diagnose and treat the disease. Collected data will help to further our blockchain platform, provide a proof of concept of assigning digital identities for the local population, and provide data ownership to study participants. By using state-of-the-art AI algorithms, Shivom and our partners will work towards the identification of biomarkers for accurate classification of patient subgroups and diabetes management apps within our platform.

 

What’s New with Our Platform?

We are thrilled by the high-interest shown by our community to test one of our first modules. Please stay tuned for more information regarding the release date and details for logging into the test module.

We look forward to providing the community with more updates next month and hearing your SCD stories.

As always, we thank you for your continued support and dedication.

Shivom Team

Exciting Changes within SHIVOM’s Management Team!

Exciting Changes within SHIVOM’s Management Team
Exciting Changes within SHIVOM’s Management Team

Here at OMIX Ventures Pvt Ltd. Project SHIVOM (Token Ticker: OMX), now post-ICO and focused on execution and growth, the leadership team has decided to make some significant management changes to ensure efficient execution and platform roll out.

We’re thrilled to announce that Henry Ines has been named as Chief Executive Officer of the global blockchain-based genomics and precision medicine services company.

Henry has deep experience and knowledge of strategic development, corporate finance, startup scaling and execution based on decades of professional experience to include years as a VC, while working in Silicon Valley and Asia as a partner at Draper Dragon Fund, DFJ Dragon Fund and DragonVenture and focusing on early stage investments in frontier technologies to include FinTech & blockchain, artificial intelligence and VR/AR. Henry continues to serve on the advisory board of multiple Blockchain and Silicon Valley tech startups and serves as a mentor to leading incubators and accelerators. Henry is also a lecturer at the Nanyang Technopreneurship Center (NTC), Nanyang Technological University (NTU) and is a Senior Member of the World Education Blockchain Association (WEBA) in Singapore. He began his career at McNeil Consumer Products Company, a subsidiary of Johnson & Johnson, and as a management consultant to Fortune 100 companies while working at Price Waterhouse LLP. Henry holds a BS in Finance from Pennsylvania State University in University Park, PA and an MBA from Duke University Fuqua School of Business in Durham, NC.

“As we enter the Post-ICO phase, I am thrilled to lead the team at SHIVOM, focusing on tackling the many problems associated with the global healthcare system through genomics. The current healthcare system continues to be inefficient and face considerable challenges. Patients’ data continues to not be secure as is evident with the recent disclosures of data breaches. Additionally, many of the prevailing genetics companies and healthcare intermediaries continue to advance business models and practices that are not necessarily consistent with and in the best interests of donors or patients. We are looking forward to being able to empower individuals by providing significant insights into their genomes and health, tools for better managing and determining who has access to personal healthcare data, and enabling individuals to better manage their health and wellness through SHIVOM’s secure blockchain-based technology platform and healthcare ecosystem.”

Dr. Axel Schumacher, company co-founder who has been CEO up to now will continue as Chief Scientific Officer, leveraging his extensive research background and expertise in genomics and precision medicine. Additionally, Dr. Natalie Pankova moves into the role of Chief Operating Officer, and will lead operations out of our London office, leveraging her background in startup operations, business development and R&D, as well as her deep involvement in the global healthcare blockchain community. We believe these roles reflect the most direct path to success for our company, our supporters, and our vision.

SHIVOM cannot wait to build the world’s largest genomics datahub to help support clinical trials, advance research and development and drug discovery process globally, and ultimately work to democratize genomics for all. It is our mission to not only maintain a secure and safe platform for our users and web-market players, but also address the genomic-based complex and rare diseases such as diabetes utilizing advanced technologies such as blockchain and artificial intelligence.

We have a very special team that is dedicated to SHIVOM’s mission and working hard to execute in accordance with the company’s roadmap and growth strategy. As a startup, we must be nimble, iterate as needed and quickly respond to dynamic and evolving conditions. We are confident about our new changes, and keen to work together in new capacities to more effectively execute on our vision and take the company to new heights.

Thank you for your continued support as we enter this new wave of development, and stay tuned into our media outlets for more exciting news coming soon!

Shivom Management Team

Shivom Partners With SingularityNET For Strengthening Genomics Medical Research and Advanced…

As a step forward towards building the world’s most extensive database of DNA records, we have partnered with SingularityNETso, the pioneers of innovations in AI and deep learning. Popular for being one of the contributors to the development of the world’s first Humanoid ‘Sophia’, SingularityNET’s AI will strengthen our toolset for providing personalized medical analytics by integrating with Shivom’s decentralized network capability.

SingularityNET’s decentralized AI network provides an open market for anyone to develop, share and monetize AI services and algorithms. This is a lucrative alliance for communities in both entities to go full throttle and unlatch optimal benefits.

Shivom Partners With SingularityNET For Strengthening Genomics Medical Research and Advanced

Going Ahead — Strengthening Shivom For The Long Term

Post successful integration of the two networks, AI agents on the SingularityNET’s decentralized platform can request biological datasets from Shivom, to execute certain analytical tasks. Similarly, a Shivom customer can seek AI analytics to be performed on the genomics data uploaded.

Such synergized networks will help boost medical professionals, researchers and the customers needs with a more accurate and more hassle-free understanding of one’s health analysis bypassing impediments in data flow necessary for this type of analysis to take place via 3rd party services.

The cross-disciplinary data sharing amidst the two networks will be driven by automated conversion between the Shivom Tokens and SingularityNET’s AGI Tokens. Followed by deep encryption of datasets in transaction coupled with cross-network reputation management, the fundamental principle of the Blockchain towards data privacy is assured.

” Shivom Co-Founder and CEO, Dr. Axel Schumacher, elaborated on the partnership and said “We are excited to work with SingularityNET. AI approaches are well suited to model the complex dependencies in the regulatory landscape of our genome and can help to predict an individual’s probability of developing certain diseases. Such information should be made actionable. As such, we are confident that AI will play a central role in our platform for achieving greater depth in the interpretation of genetic information such as how an individual’s genes may impact their lifestyle decisions or help their healthcare providers to design of potential therapies.”

SingularityNET CEO, Dr. Ben Goertzel pitched in saying, “ “We are enthused to have the opportunity to support Shivom’s vision of next-era genomic research. The Shivom vision synergizes beautifully with the SingularityNET vision; the integration of Shivom’s technology, tools, and data with our SingularityNET mind-network will add more scope and intelligence into the field of personalized medical analytics.I. Together, we can achieve great things for medical science by utilizing high-quality datasets, SingularityNET’s algorithms and customer base for biomedical analytics services, and Shivom’s genomics-focused software.”

What’s Ahead?

In our mission to unlock the data stored in billions of genetic codes across the globe, this alliance is a breakthrough move. As partners, we really look forward to redefining medical research as we usher in a new era of healthcare and maximize the capabilities of Shivom’s genetic data storage and analysis platform.

Shivom is pushing policies for reimbursement of genetic testing

One of the main challenges for the development and implementation of precision medicine is the lack of reimbursement for genetic tests in most countries. There are many examples of clinically useful information available through newly developed genetic tests. While some health insurance plans in the US cover the cost of genetic testing when recommended by a physician, other forms of genome sequencing are usually not included, especially not in the EU and most Asian countries.

Without question, genomic medicine will revolutionize clinical practice in the coming years. As such, it is essential that genetic testing reimbursement processes are improved, particularly for whole-genome sequencing. To change the status-quo, recently, Shivom, together with other entrepreneurs from all over the EU including the Netherlands, Italy, France, Germany, UK, and Hungary joined forces with experts from the healthcare industry, including insurers and policymakers during a policy perspective meeting of the European Commission in The Hague/Netherlands.

https://ideasfrom.eu/value-track-personalised-medicine/

A hot topic of this policy perspective meeting was the reimbursement of genetic tests because uncertain or inadequate reimbursement by public and private payers of genetic tests creates one of the most significant barriers to the development and adoption of precision medicine. We at Shivom think that genome sequencing, in general, should be subject to reimbursement, including direct to consumer (DTC) genetic testing, which enables consumers or patients to access their genetic information directly from a testing company.

Shivom is pushing policies for reimbursement of genetic testing

Dr. Axel Schumacher, CEO of Shivom: “To have access to your DNA sequence may be necessary for many reasons, including for predicting individual predispositions to diseases or conditions, or for preventive, therapeutic, reproductive, or life planning measures. Lack of a positive reimbursement decision disincentivizes patient participation and creates a barrier to the use of modern genomic medicine by authorizing clinicians and patients. As long as a whole genome sequencing test is scientifically valid (of high quality), it should be reimbursed; even more so because it has to be done only once in a person’s life.”

At Shivom, we strongly believe that now is the time to foster a new era of precision medicine through policy changes that empower patients, researchers and healthcare providers to work together toward development of personalized care.

Shivom’s Referral Program — Earn More Through Your Network

Congratulations on joining and contributing to the Shivom’s presale!

Now is when the fun begins. We are offering every Shivom user a chance to earn more bonuses through referrals. Our referral program is simple and has the potential for high returns. All you have to do is share the unique referral link you receive in your email after you have created an account on the Shivom dashboard.

If you still haven’t registered for the OmiX presale you can visit the Tokensale dashboard — https://tokensale.shivom.io/ and complete the registration process.


Referral program is based on your network!

When you receive your referral link, you can send this link to your friends and family and receive 5% bonus every time those you referred purchase OmiX tokens from their account.

The referrals program is not limited to a one-time reward. This is a 3-tier referral code that plays on network effects, which means you will get a 5% bonus for every new user and they also receive a bonus amounting to 5%. They can also share the unique referral link they receive with their friends, which in turn gives them 5% bonus, and gives you 4%. Subsequent sharing of the referral link by those friends will allow you to still enjoy a 3% bonus on their purchased tokens.

Overall, for three subsequent sharings of referral links in your network will allow you to receive a bonus of 5%, 4%, and 3% from your connections.

For any queries regarding Shivom’s referral program, please contact us at:

invest@shivom.io

We are thrilled to have you on board the Shivom community, and are excited to be able to reward our biggest supporters!

Everything You Need To Know About The Shivom Presale

The Shivom Presale is scheduled to go live on Monday April 16th, 2018 6:00PM GMT.


Registration is still open and you can register now.

We will not publish the ETH address for contribution on any social media or our Telegram group.

We recommend you join our Telegram community and follow us on twitter so that you don’t miss any updates for more updates and recommendations in the run up to the pre and the public sale.

Conditions of the OmiX Crowdsale:

  • 990 Million OmiX tokens for sale at 1 ETH = 7000 OmiX
  • First 15 000 ETH worth of tokens will be sold at 10% discount on 16th April Bonus will decrease by 1% each day
  • Hard cap: 75,000 ETH
  • Soft Cap : 20,000 ETH ( Already achieved)
  • Minimum transaction limit: 0.00014286 ETH
  • Min individual cap: 1 ETH
  • Caps will be reviewed after 24 hours, if tokens remain

How to begin?

  1. Create an account — Register on the Shivom website and create an account at: https://tokensale.shivom.io/. Verify your email address by clicking on the email confirmation you receive.
  2. Complete KYC — You will only be able to get your OmiX tokens after a verified KYC. You will still be able to purchase OmiX before your KYC has been verified, however your OmiX tokens will only appear in your wallet AFTER you have passed verification. After you have created your account, you need to further provide your proof of ID with a photograph and additional information. It may take up to 24 hours for your KYC to be completed and your identity to be verified. Please check your spam folder in case you don’t receive the KYC confirmation email in your inbox. If you receive an email within 24 hours which says that your identity has not been verified, please re-submit the KYC application by following the instructions in your email.
  3. We are accepting ETH, BTC, DASH, LISK, LTC, QTUM, NEM, MONERO, RIPPLE, VERGE, ZCASH, NEO
  4. Wait for the launch time (April 16th 1pm GMT). Once you’ve registered and submitted KYC, you can log in to your account on https://tokensale.shivom.io at the sale start time and you will be ready to buy OmiX. To buy OMX in the token sale using our platform, please follow step by step guide at this link
  5. We recommend you join our Telegram community and follow us on Twitter so that you don’t miss any updates.

Register on our Tokensale Dashboard

Hello Shivom Community!

We noticed that many of you have already joined our whitelist and have signed up for the presale event scheduled to go live on April 16th, 2018 at 1 PM GMT. To continue with your journey as part of our community we recommend that you register on our Tokensale Dashboard as soon as possible to ensure that your purchase of OmiX tokens goes smoothly.

Here you will be able to complete your KYC, which is a mandatory step before purchasing tokens, and subsequently, the token purchase will be available to you once the sale goes live.

Visit https://tokensale.shivom.io/ page and follow the instructions.


The Shivom team is there to answer any questions you may have or any assistance that you may need with KYC procedure.

You can contact us at: invest@shivom.io